NASDAQ$ARWR
Arrowhead Pharmaceuticals Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported fiscal 2022 second quarter results.
Arrowhead Pharmaceuticals reported a net income of $44.366 million and revenue of $151.805 million for the fiscal second quarter ended March 31, 2022.
- Initiated the PALISADE Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome.
- Completed enrollment of 204 patients in the Phase 2b ARCHES-2 clinical study of ARO-ANG3 for patients with mixed dyslipidemia.
- Initiated the Phase 2 GATEWAY clinical study of ARO-ANG3 in patients with homozygous familial hypercholesterolemia (HoFH).
- Initiated a Phase 1/2 study of ARO-C3 for various complement mediated diseases.
Headline financials
Revenue & EPS history
Arrowhead Pharmaceuticals · Revenue · Quarterly
$152M
Forward guidance
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+0.0%
Avg return
Earnings day
+4.2%
Avg return
5 days after
+10.8%
Avg return
30 days after
38%
24 / 64 earnings
Positive
+39.2%
Q4 2024
Best reaction
-26.7%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.6% | +0.1% | -6.1% | |
| Q1 2026 | -0.2% | -4.8% | -7.5% | |
| Q4 2025 | +23.2% | +20.2% | +49.9% | |
| Q2 2025 | +9.4% | +12.5% | +16.1% | |
| Q1 2025 | -5.2% | +0.2% | -24.3% | |
| Q4 2024 | +39.2% | +38.5% | +3.9% | |
| Q3 2024 | -6.4% | -8.6% | -11.1% | |
| Q2 2024 | -12.5% | -9.2% | -5.2% | |
| Q1 2024 | -1.2% | +1.7% | +3.7% | |
| Q4 2023 | -26.7% | -13.8% | +5.8% | |
| Q3 2023 | -13.1% | -8.8% | -7.7% | |
| Q2 2023 | +12.5% | +15.8% | -2.9% | |
| Q1 2023 | -8.5% | -9.9% | -19.3% | |
| Q4 2022 | +1.7% | +15.0% | +27.3% | |
| Q3 2022 | +3.6% | +2.5% | -11.1% | |
| Q2 2022 | -11.5% | -3.3% | -0.7% | |
| Q1 2022 | -11.1% | -5.4% | -22.1% | |
| Q4 2021 | -0.3% | +1.3% | -1.8% | |
| Q3 2021 | -2.0% | -7.4% | +2.2% | |
| Q2 2021 | -5.4% | -5.5% | +3.2% | |
| Q1 2021 | +12.6% | +11.8% | -14.1% | |
| Q4 2020 | -12.2% | -8.4% | +24.1% | |
| Q3 2020 | -7.0% | -8.5% | -18.3% | |
| Q2 2020 | -0.3% | +5.0% | -0.5% | |
| Q1 2020 | -6.4% | -2.4% | -23.9% | |
| Q4 2019 | +37.6% | +48.4% | +31.2% | |
| Q3 2019 | -2.1% | -0.2% | +17.6% | |
| Q2 2019 | +8.0% | +0.1% | +50.2% | |
| Q1 2019 | +13.2% | +25.4% | +33.0% | |
| Q4 2018 | +11.2% | +4.8% | +9.8% | |
| Q3 2018 | +13.2% | +18.6% | +36.2% | |
| Q2 2018 | +15.8% | +27.2% | +33.5% | |
| Q1 2018 | -6.2% | -3.4% | +30.9% | |
| Q4 2017 | -3.1% | -10.5% | +43.6% | |
| Q3 2017 | +8.9% | +13.6% | +69.2% | |
| Q2 2017 | +13.5% | +6.4% | +3.8% | |
| Q1 2017 | +3.2% | +3.7% | +12.1% | |
| Q4 2016 | +0.0% | -1.6% | +62.2% | |
| Q3 2016 | -1.2% | +1.0% | +29.7% | |
| Q2 2016 | -3.1% | — | — | |
| Q1 2016 | -0.9% | — | — | |
| Q4 2015 | -1.1% | — | — | |
| Q3 2015 | +12.1% | — | — | |
| Q2 2015 | -10.9% | — | — | |
| Q1 2015 | -1.1% | — | — | |
| Q4 2014 | -6.2% | — | — | |
| Q3 2014 | +1.2% | — | — | |
| Q2 2014 | -10.7% | — | — | |
| Q1 2014 | -2.6% | — | — | |
| Q4 2013 | +7.3% | — | — | |
| Q3 2013 | +2.5% | — | — | |
| Q2 2013 | +10.2% | — | — | |
| Q1 2013 | -1.8% | — | — | |
| Q4 2012 | -7.2% | — | — | |
| Q3 2012 | -16.8% | — | — | |
| Q2 2012 | -4.5% | — | — | |
| Q1 2012 | -1.4% | — | — | |
| Q4 2011 | +0.5% | — | — | |
| Q2 2011 | +0.5% | — | — | |
| Q3 2011 | -12.4% | — | — | |
| Q3 2010 | -12.4% | — | — | |
| Q4 2010 | -12.4% | — | — | |
| Q1 2011 | -5.6% | — | — | |
| Q2 2010 | -8.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro